Veradigm Earnings Call Transcripts
Fiscal Year 2026
-
Achieved timely filing of 2023 and 2024 10-Ks, setting the stage for 2025 and 2026 filings and a potential relisting. Revenue and profitability remain flat, but operational improvements, AI adoption, and cost actions are expected to drive margin expansion and growth in 2026.
-
Reset, Recover, Reignite plan is underway, with discontinued low-revenue products and capital reallocated to growth bets. 2025 revenue was flat, but operational and AI-driven initiatives are expected to drive growth and profitability in 2026. SEC filing progress continues, with the Super K as the next milestone.
Fiscal Year 2025
-
Revenue remains stable with strong recurring streams and a net cash positive position. Strategic priorities include improving profitability, reigniting growth, and achieving SEC filing compliance, with relisting targeted for 2026. Leadership emphasizes operational discipline and leveraging data assets.
-
Q1 2025 saw over $30 million in new contract value, flat overall revenue, and strong recurring revenue. Operational improvements, audit remediation, and a new credit facility support stability, while growth continues in payer, provider, and life sciences segments.
Fiscal Year 2024
-
Audited 2022 and unaudited 2023–2024 results show 2024 revenue and EBITDA below guidance due to attrition, implementation delays, and sector softness. Remediation of internal controls and audit completion expected by 2026, with 2025 revenue flat and net cash positive.